TKI联合重组人血管内皮抑制素在TKI治疗后局部进展晚期肺腺癌患者的疗效  

The clinical efficacy of TKI combined with Endostar in treatment of local progressive advanced lung adenocarcinoma

作　　者：赵悦[1] 谢赟[2] 贾殿军 张煦涵 卢会杰 李宝辉[1] 石亮[1] ZHAO Yue;XIE Yun;JIA Dianjun(Cangzhou Central Hospital,Hebei,Cangzhou 061000,China;不详)

机构地区：[1]河北省沧州市中心医院,061000 [2]河北省疾病预防控制中心

出　　处：《河北医药》2022年第3期409-412,共4页Hebei Medical Journal

基　　金：河北省卫生和计划生育委员会科研基金项目(编号:20200331)。

摘　　要：目的探讨酪氨酸激酶抑制剂(TKI)联合重组人血管骨皮抑制素(恩度)在TKI治疗后出现局部进展的晚期肺腺癌患者中的临床疗效。方法选取2018年1月至2019年8月收治的TKI治疗后出现局部进展的晚期肺腺癌患者18例,给予TKI联合恩度治疗,同时给予局部放疗,观察其治疗效果及不良反应情况。结果全组18例患者中位PFS 10.5个月,未见不可耐受的不良反应发生,放射性脑损伤3个月发生率为6.25%,6个月发生率为12.5%,患者均未观察到认知功能障碍。结论TKI联合恩度在TKI治疗后出现局部进展的晚期肺腺癌患者中取得了较好的中位PFS,不良反应可以耐受,放射性脑损伤发生率较低。Objective To investigate the clinical efficacy of TKI combined with Endostar in treatment of local progressive advanced lung adenocarcinoma.Methods Eighteen patients with advanced lung adenocarcinoma with local progressive lung adenocarcinoma after TKI treatment who were treated in our hospital from January 2018 to August 2019 enrolled in the study,who were treated by TKI combined with Endostar as well as local radiotherapy,then the therapeutic effects and adverse reactions were analyzed.Results Of the 18 patients,the median PFS was 10.5 months,and no intolerable adverse reactions were observed.The incidence rate of radiation brain injury at 3 months was 6.25%,and the incidence at 6 months was 12.5%.No cognitive impairment was observed in the 18 patients.Conclusion TKI combined with Endostar can obtain better median PFS in patients with advanced lung adenocarcinoma with local progression after TKI treatment,with tolerable adverse reactions and lower incidence rate of radiation brain injury,which needs to be further verified in a large sample size randomized controlled study.

关 键 词：酪氨酸激酶抑制剂 恩度 晚期肺腺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]